Literature DB >> 22566286

Impact of severity of renal dysfunction on determinants of in-hospital mortality among patients undergoing percutaneous coronary intervention.

Puja B Parikh1, Allen Jeremias, Srihari S Naidu, Sorin J Brener, Fabio Lima, Richard A Shlofmitz, Thomas Pappas, Kevin P Marzo, Luis Gruberg.   

Abstract

BACKGROUND: Chronic kidney disease (CKD) is a known prognostic indicator of poor outcomes following percutaneous coronary intervention (PCI) for coronary artery disease. However, it is unclear whether other predictors of mortality differ among patients with varying degrees of renal impairment. Thus, we aimed to identify determinants of in-hospital mortality which are specific to patients with preserved renal function, moderate CKD, or end stage renal disease (ESRD) on dialysis, undergoing PCI.
METHODS: The study population included 25,018 patients who underwent PCI between January 1, 2004, and December 31, 2007, at four New York State hospitals. The primary endpoint of the study was in-hospital mortality.
RESULTS: A total of 474 (1.9%) patients had ESRD on dialysis, 6,596 (26.4%) had moderate CKD (GFR<60 ml/min/1.73 m(2) ), and 17,948 (71.7%) had preserved renal function (GFR>60 ml/min/1.73 m(2) ). Patients with ESRD and moderate CKD were older, more often male, and had higher rates of prior coronary revascularization, peripheral vascular disease, congestive heart failure, prior stroke, and diabetes than those with preserved function. All-cause in-hospital mortality rates were significantly higher in patients with ESRD and moderate CKD compared to patients with GFR >60 ml/min/1.73 m(2) (2.1% and 1.3%, respectively vs. 0.3%, p < 0.001). In multivariable analysis, ESRD (OR: 3.68, 95% CI 1.62-8.36) and moderate CKD (OR: 2.92, 95% CI 1.91-4.46) were independently associated with higher rates of in-hospital mortality. Independent predictors of mortality were markedly distinct in each group and included female gender and myocardial infarction within the past 72 hr in the ESRD group, versus left ventricular ejection fraction, peripheral vascular disease, congestive heart failure, emergency PCI, and absence of prior PCI in the moderate CKD group and age, prior bypass graft surgery, congestive heart failure, emergency PCI, and absence of prior myocardial infarction in patients with preserved renal function.
CONCLUSIONS: Patients with moderate CKD or ESRD undergoing PCI have an approximately threefold increase in the risk of in-hospital mortality compared with patients with preserved renal function, with radically different mortality predictors existing for varying levels of renal function.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22566286     DOI: 10.1002/ccd.23394

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  16 in total

1.  Incremental prognostic information from kidney function in patients with new onset coronary heart disease.

Authors:  Mark A Hlatky; David Shilane; Tara I Chang; Derek Boothroyd; Alan S Go
Journal:  Am Heart J       Date:  2013-10-23       Impact factor: 4.749

2.  Determinants of Mortality in Patients with Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention.

Authors:  Alexandros Papachristidis; Wei Yao Lim; Christos Voukalis; Salma Ayis; Christopher Laing; Roby D Rakhit
Journal:  Cardiorenal Med       Date:  2016-02-19       Impact factor: 2.041

3.  Deterioration of renal function at stent implantation can predict long-term outcome after stent thrombosis.

Authors:  Vojko Kanic; Meta Penko; Franjo Husam Naji; Robert Ekart; Zlatka Kanic; Dejan Dinevski; Radovan Hojs
Journal:  Wien Klin Wochenschr       Date:  2015-09-16       Impact factor: 1.704

4.  Analysis of the Clinical Characteristics of Patients with Acute Coronary Syndrome in Different States of Renal Function.

Authors:  L-H Hu; L-J Zhang; Z-T Jin; W Yang; L-N Zhang; C-Y Lu
Journal:  West Indian Med J       Date:  2015-05-06       Impact factor: 0.171

5.  Outcomes with prolonged clopidogrel therapy after coronary stenting in patients with chronic kidney disease.

Authors:  Omar K Siddiqi; Kyle J Smoot; Alyssa B Dufour; Kelly Cho; Melissa Young; David R Gagnon; Samantha Ly; Sara Temiyasathit; David P Faxon; J Michael Gaziano; Scott Kinlay
Journal:  Heart       Date:  2015-07-24       Impact factor: 5.994

6.  Chronic Kidney Disease, But Not Diabetes, Can Predict 30-Day Outcomes in Patients with ST-Elevation Myocardial Infarction after Primary Percutaneous Coronary Intervention: A Single-Center Experience.

Authors:  Cheng-Chung Hung; Wei-Chun Huang; Kuan-Rau Chiou; Chin-Chang Cheng; Feng-Yu Kuo; Jin-Shiou Yang; Ko-Long Lin; Cheng-Hung Chiang; Shin-Hung Hsiao; Chi-Cheng Lai; Tzu-Wen Lin; Guang-Yuan Mar; Chuen-Wang Chiou; Chun-Peng Liu
Journal:  Acta Cardiol Sin       Date:  2013-09       Impact factor: 2.672

7.  Renal Impairment and Prognosis of Patients with Atrial Fibrillation Undergoing Coronary Intervention - The AFCAS Trial.

Authors:  Heli M Lahtela; Tuomas O Kiviniemi; Marja K Puurunen; Axel Schlitt; Andrea Rubboli; Antti Ylitalo; José Valencia; Gregory Y H Lip; K E Juhani Airaksinen
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

8.  Clinical Impact of Rapid Reduction of Low-Density Lipoprotein Cholesterol Level on Long-Term Outcome of Acute Myocardial Infarction in the Statin Era: Subanalysis of the ALPS-AMI Study.

Authors:  Takashi Miura; Atsushi Izawa; Hirohiko Motoki; Yusuke Miyashita; Yuichiro Kashima; Souichiro Ebisawa; Takeshi Tomita; Jun Koyama; Uichi Ikeda
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

Review 9.  Coronary artery disease in patients with chronic kidney disease: a clinical update.

Authors:  Qiangjun Cai; Venkata K Mukku; Masood Ahmad
Journal:  Curr Cardiol Rev       Date:  2013-11

10.  Mortality and treatment costs of hospitalized chronic kidney disease patients between the three major health insurance schemes in Thailand.

Authors:  Sirirat Anutrakulchai; Pisaln Mairiang; Cholatip Pongskul; Kaewjai Thepsuthammarat; Chitranon Chan-On; Bandit Thinkhamrop
Journal:  BMC Health Serv Res       Date:  2016-09-29       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.